LDG Laboratories Dr. Gansauge – Dendritic Cell Therapy & Oncology Immunotherapy Center

LDG Laboratories Dr. Gansauge is a specialized oncology immunotherapy center located in Berg, Germany, offering advanced personalized cancer treatment through dendritic cell therapy. The clinic is internationally recognized for its proprietary LANEX-DC® immunotherapy program and for maintaining a fully regulated, government-approved laboratory dedicated exclusively to cell-based cancer therapies.

With over two decades of clinical experience and more than 5,000 patients treated, LDG has established itself as a leading European facility focused on innovative immunotherapy research and treatment development. The clinic operates under strict German regulatory standards and integrates scientific research, laboratory innovation, and personalized patient care within a single in-house treatment system.

Clinic Overview

LDG Laboratories Dr. Gansauge is led by Prof. Dr. Frank Gansauge, a globally recognized specialist in dendritic cell therapy and clinical oncology immunotherapy. The center focuses on individualized cancer care using immune-based treatments designed to support the body’s natural tumor-targeting mechanisms.

The facility combines advanced laboratory infrastructure, scientific research expertise, and patient-centered treatment planning. All phases of therapy — from consultation and cell preparation to treatment administration — are performed under direct clinical supervision without outsourcing, ensuring consistent quality control and treatment precision.

Key Achievements and Credentials

• Over 5,000 cancer patients treated using dendritic cell therapy
• More than 20 years of clinical and laboratory experience
• Government-approved and GMP-certified laboratory facility
• Winner of multiple German Business Awards
• Five published medical white papers focused on dendritic cell therapy
• Over 150 scientific publications in immunotherapy and oncology research
• Observational clinical data showing approximately 60–65% disease stabilization or improvement in selected advanced cancer patients

Clinical outcomes may vary based on tumor type, disease stage, immune system response, and individual patient factors.

Leadership and Medical Team

LDG Laboratories is directed by Prof. Dr. Frank Gansauge, an internationally recognized authority in dendritic cell therapy research and clinical application. His work focuses on advancing personalized immunotherapy treatments that integrate laboratory science with clinical oncology.

The clinic is supported by a multidisciplinary team of specialists in:

• Oncology
• Immunology
• Cellular therapy research
• Molecular diagnostics
• Laboratory science
• Personalized cancer treatment planning

Every patient receives individualized consultation directly involving senior medical leadership and specialized immunotherapy experts.

LANEX-DC® Dendritic Cell Therapy

LDG’s proprietary LANEX-DC® therapy is a personalized immunotherapy approach designed to stimulate the immune system’s ability to identify and respond to cancer-specific markers.

How Dendritic Cell Therapy Works

Dendritic cells play a crucial role in immune system activation. The therapy involves collecting immune cells from the patient’s blood and processing them in a certified laboratory to develop tumor-specific immune response signals.

Once prepared, these activated dendritic cells are reintroduced into the patient’s body to help enhance immune recognition of cancer cells.

Treatment Process

Step 1: Medical Consultation and Blood Collection

Patients begin with a clinical consultation and medical evaluation. A blood sample is collected, and supportive infusion therapy may be administered during the visit.

Step 2: Laboratory Cell Preparation

Immune cells are processed in LDG’s GMP-certified laboratory where dendritic cells are exposed to cancer-specific markers derived from the patient’s biological samples.

Step 3: Dendritic Cell Administration

The matured dendritic cells are administered through a minimally invasive injection into the abdominal skin, followed by supportive infusion therapy to support immune function.

State-of-the-Art Laboratory Facility

LDG operates one of only a limited number of government-regulated dendritic cell laboratories in Europe. The laboratory spans over 600 square meters and meets stringent GMP (Good Manufacturing Practice) standards.

Laboratory Advantages

• Fully regulated German government-approved facility
• Exclusive in-house processing for LDG patients
• Strict quality control throughout cell development
• Advanced biotechnology equipment for personalized cell preparation
• Integrated temperature-controlled transport system ensuring cell stability

Fresh Cell Treatment Approach

LDG prioritizes the use of freshly prepared dendritic cells whenever medically possible to maintain optimal cell viability and immune activation potential.

In situations requiring treatment scheduling adjustments or unexpected travel delays, cryopreservation options are available to ensure therapy continuity. The clinic maintains rapid transport between laboratory and treatment facility, typically within 1.5 hours.

Conditions and Patient Eligibility

Dendritic Cell Therapy is a personalized treatment option that may be considered for patients diagnosed with various types of cancer across different age groups.

The therapy is often explored as a complementary treatment alongside conventional cancer therapies or as part of an integrated treatment plan. Individual suitability is determined following medical evaluation and immunological assessment.

Potential eligibility factors may include:

• Cancer type and biological profile
• Disease stage and progression
• Patient immune response capability
• Overall health condition
• Prior or ongoing cancer treatments

Integration with Conventional Cancer Treatments

LDG integrates dendritic cell therapy alongside traditional oncology treatments when medically appropriate.

Chemotherapy Integration

Dendritic cell therapy may be scheduled between chemotherapy cycles and is typically compatible with ongoing chemotherapy treatment plans.

Immunotherapy Combination

Both therapies aim to stimulate immune system activity. Combined use may enhance immune response against cancer cells in selected cases.

Radiotherapy Support

Radiotherapy may increase tumor antigen exposure, which can potentially improve dendritic cell therapy immune targeting.

Treatment Environment and Patient Experience

LDG’s clinic is located in Berg, a peaceful lakeside town near Lake Starnberg, approximately 30 minutes from Munich. The clinic environment is designed to promote comfort, privacy, and reduced stress for patients undergoing treatment.

Patient Comfort Features

• Private consultation and treatment rooms
• Calm, therapeutic clinic setting
• Modern diagnostic and treatment technology
• Personalized patient support services
• Multilingual care coordination for international patients

Research and Scientific Contribution

LDG Laboratories maintains a strong focus on research and clinical evidence. The center has contributed to global immunotherapy development through:

• Five dedicated white papers on dendritic cell therapy outcomes
• More than 150 scientific publications related to oncology and cellular immunotherapy
• Continuous clinical observation studies evaluating treatment response and safety outcomes

Personalized Cancer Care Approach

LDG emphasizes individualized treatment planning, recognizing that cancer therapy outcomes vary significantly between patients. The clinic develops personalized therapy protocols based on detailed clinical evaluation, tumor characteristics, and immune system analysis.

The treatment approach focuses on supporting the patient’s immune system while maintaining quality of life and treatment tolerability.

International Patient Services

LDG provides structured medical travel coordination for international patients seeking specialized immunotherapy treatment in Germany. Services include:

• Personalized medical case evaluation
• Treatment scheduling coordination
• Travel guidance and logistics assistance
• Translation and international patient support
• Post-treatment follow-up planning

Safety, Compliance, and Regulation

LDG operates under strict German healthcare regulatory standards and GMP laboratory compliance requirements. These regulatory frameworks ensure patient safety, treatment quality, and ethical clinical practice.

All therapies are performed within the clinic’s certified infrastructure under direct medical supervision.

Location and Accessibility

LDG Laboratories Dr. Gansauge is located in Berg, Bavaria, Germany, near the internationally recognized Lake Starnberg region. The clinic is easily accessible from Munich via road, rail, and international air travel routes.

The tranquil lakeside setting supports patient recovery while providing access to advanced German medical infrastructure.

Why Patients Choose LDG Laboratories

Patients often consider LDG for its combination of advanced immunotherapy expertise, personalized treatment protocols, and integrated laboratory and clinical care system. The clinic’s commitment to research, innovation, and individualized patient care has contributed to its recognition within the European immunotherapy field.